Doctors prescribed it for weight loss, but it may also cut breast cancer risk by 30%

Nobody handed Ozempic a second job. But it appears to have taken one anyway.

A large new study published in early June 2026 and presented at one of the most prominent cancer conferences in the world found that women taking GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound were about 30% less likely to develop breast cancer than women who weren’t taking them. 

The finding wasn’t the point of the original research. It emerged from health records. And it has landed in the medical community like a slow, building thunderclap, not quite certain, but impossible to ignore.

What the Study Found

Researchers at the University of Pennsylvania Perelman School of Medicine analyzed electronic health records from more than 111,000 women aged 45 to 80, all of whom had a BMI of 25 or higher and underwent breast imaging through the Penn Medicine health system between January 2022 and June 2025. Roughly 15,000 of those women had documented GLP-1 prescriptions. The remaining 96,000 had none.

The numbers told a consistent story. In the matched cohort where researchers paired GLP-1 users with non-users who shared similar age, race, BMI, breast density, and diabetes status, about 1.62% of GLP-1 users were diagnosed with breast cancer during the study period, compared to 2.31% of non-users. That works out to roughly 7 fewer cancers per 1,000 women and an odds ratio of 0.70, corresponding to about a 30% reduction in risk.

Across the full, unmatched study population, the gap was even larger, a 35% reduction.

The findings were published in JCO Oncology Practice and presented at the 2026 American Society of Clinical Oncology Annual Meeting. Lead researcher Dr. Elizabeth McDonald, a professor of radiology and practicing breast radiologist at Penn’s Abramson Cancer Center, was measured in her conclusions: 

“While our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, it does add to the growing body of evidence suggesting that it’s worth investigating these weight-loss drugs as potential cancer prevention tools.”

Worth noting: a separate analysis looking specifically at women with diabetes found risk reductions ranging from 30% to as high as 47%. That range has drawn significant attention from oncologists seeking to understand exactly what these drugs are doing.

Why This Isn’t Entirely Surprising

To understand why researchers are taking this seriously rather than dismissing it as a coincidence, it helps to understand the relationship between excess weight and breast cancer. That relationship is well-established and significant.

Excess body weight is one of the few confirmed, modifiable risk factors for breast cancer, particularly after menopause. Fat cells produce estrogen, and extra fat means more estrogen circulating in the body, which can fuel the growth of hormone receptor-positive tumors, the most common type.

Research consistently shows that overweight postmenopausal women face meaningfully elevated risk compared to women at a healthy weight. The heavier the person, the greater the risk.

The American Institute for Cancer Research has estimated that a third of U.S. breast cancers could potentially be prevented if women maintained a healthy weight throughout life, stayed physically active, and avoided alcohol. Given that over two-thirds of U.S. women are currently overweight or obese, the scale of that potential is enormous.

GLP-1 drugs were designed primarily to control blood sugar and, as a secondary effect, drive significant weight loss by mimicking the body’s natural appetite-regulating hormones.

If weight is a major breast cancer driver, it stands to reason that a drug producing sustained, meaningful weight loss might reduce that risk. But the science here is suggesting something more complicated and more interesting than simple math.

It May Not Just Be the Weight Loss

Here’s where things get genuinely fascinating. In some analyses, the protective association held even after researchers adjusted for BMI and weight change. That suggests the drugs may be doing something beyond just helping women lose pounds.

Researchers have identified several biological pathways that could explain an independent effect. GLP-1 agonists are known to reduce chronic low-grade inflammation, which has long been linked to cancer development. 

They improve insulin sensitivity and reduce visceral fat, the metabolically active fat stored around organs, which creates a less hospitable environment for tumor initiation. There may also be direct effects on cancer cell biology that researchers are only beginning to map.

This pattern is not unique to breast cancer. Earlier research has connected GLP-1 drugs to reduced risk for certain other cancers, including colon cancer. A UC San Diego study published in late 2025 suggested that GLP-1 users with colon cancer had dramatically lower mortality. 

The list of conditions these drugs appear to protect against, cardiovascular disease, kidney disease, sleep apnea, and now potentially cancer, keeps expanding in ways that weren’t anticipated when semaglutide was first approved for diabetes management.

The Limits of What We Know

It’s important to be clear about what this study is and isn’t. It is observational, meaning researchers looked at what happened to real women over time. They did not randomly assign anyone to take a drug and watch what followed. Observational research can identify associations and generate hypotheses. It cannot establish cause and effect.

There are also factors the study couldn’t fully account for. Researchers didn’t track which specific GLP-1 drug each woman used, what dose she was on, or how long she’d been taking it. Some women in the non-user group may have obtained GLP-1 medications outside the Penn Medicine system. 

And women who are prescribed these drugs may differ from non-users in ways that aren’t fully captured by matching on BMI and diabetes status alone, including health-seeking behavior, diet, exercise, and access to care.

Dr. McDonald’s team acknowledged these limitations explicitly. The finding has prompted a clinical trial designed to test whether the association reflects a true protective effect, which is exactly the appropriate next step.

Why This Matters Beyond the Headlines

Even with those caveats, the implications are worth sitting with.

GLP-1 drugs are already being taken by tens of millions of people. Their use has expanded rapidly from diabetes management to obesity treatment, and the medications are now among the most prescribed drugs in the United States. 

The infrastructure of access, prescribing, insurance coverage, and manufacturing is being built out in real time. If even a portion of that protective association proves causal, the public health implications are substantial.

Breast cancer remains the most commonly diagnosed cancer among women in the United States. It is also a disease where early detection and prevention matter enormously.

The toolbox for prevention is currently limited to lifestyle changes, genetic screening for high-risk individuals, and, in some cases, preventive medications such as tamoxifen, which carries its own significant side-effect profile.

A drug that millions of women are already taking for another reason, and that might also reduce breast cancer risk, would represent a genuinely new category of option.

That said, GLP-1 drugs are not without their own concerns. They come with gastrointestinal side effects that many users find difficult to manage, particularly in the early months. There are ongoing questions about long-term use, weight regain after stopping, and access. 

These medications remain expensive and are not universally covered by insurance. They are not a solution for everyone, and nobody should read this research as a prescription.

What Comes Next

The clinical trial that follows this study will be the real test. Prospective research where women are assigned to GLP-1 treatment or placebo and followed over years can actually determine whether the drugs are causing the risk reduction or simply associated with it. 

That work will take time. In the meantime, women who are already taking GLP-1 drugs for weight management or diabetes can hold this finding as cautiously encouraging context, not medical guidance.

What the Penn Medicine study does, perhaps more than anything, is reframe how the medical community thinks about this class of drugs. They were built for one purpose. They appear to be doing several others. The question is no longer whether GLP-1 medications have effects beyond blood sugar and appetite. It’s how many effects they have, and which ones will prove durable when put to the rigorous test of a clinical trial.

The data right now says: 30% lower odds. The science says: let’s find out why.

Disclaimer – This list is solely the author’s opinion based on research and publicly available information. It is not intended to be professional advice.

Like our content? Be sure to follow us